DK169609B1 - Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom - Google Patents

Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom Download PDF

Info

Publication number: DK169609B1
Authority: DK; Denmark
Prior art keywords: compound; disease; treatment; parkinson; hydrogen
Prior art date: 1987-05-21

Application number

DK275488A

Other languages

Danish (da)

English (en)

Other versions

DK275488A (da

DK275488D0 (da

Inventor

David Andrew Arlwydd Owen

Original Assignee

Smith Kline French Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-05-21

Filing date

1988-05-19

Publication date

1994-12-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10617727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK169609(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-05-19 Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab

1988-05-19 Publication of DK275488D0 publication Critical patent/DK275488D0/da

1988-11-22 Publication of DK275488A publication Critical patent/DK275488A/da

1994-12-27 Application granted granted Critical

1994-12-27 Publication of DK169609B1 publication Critical patent/DK169609B1/da

Links

239000003814 drug Substances 0.000 title claims abstract description 11
208000018737 Parkinson disease Diseases 0.000 title claims abstract description 8
-1 4-Substituted Indolones Chemical class 0.000 title claims description 5
229940079593 drug Drugs 0.000 title claims description 5
238000011282 treatment Methods 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 13
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
239000001257 hydrogen Substances 0.000 claims abstract description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
125000000217 alkyl group Chemical group 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
150000001875 compounds Chemical class 0.000 abstract description 18
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
229940126062 Compound A Drugs 0.000 description 27
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 27
230000000694 effects Effects 0.000 description 22
238000002474 experimental method Methods 0.000 description 15
230000006742 locomotor activity Effects 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 10
229960002802 bromocriptine Drugs 0.000 description 10
239000000939 antiparkinson agent Substances 0.000 description 9
230000006399 behavior Effects 0.000 description 9
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 8
230000001430 anti-depressive effect Effects 0.000 description 8
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
230000002269 spontaneous effect Effects 0.000 description 8
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 7
208000027089 Parkinsonian disease Diseases 0.000 description 7
206010034010 Parkinsonism Diseases 0.000 description 7
229940025084 amphetamine Drugs 0.000 description 7
230000000949 anxiolytic effect Effects 0.000 description 7
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 6
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000003136 dopamine receptor stimulating agent Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
229960004046 apomorphine Drugs 0.000 description 5
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 5
230000033001 locomotion Effects 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
229940035678 anti-parkinson drug Drugs 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
229960003638 dopamine Drugs 0.000 description 4
229940052760 dopamine agonists Drugs 0.000 description 4
230000004886 head movement Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
230000003518 presynaptic effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
208000012661 Dyskinesia Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000555745 Sciuridae Species 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
230000000648 anti-parkinson Effects 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000006735 deficit Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
150000005624 indolones Chemical class 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
210000001009 nucleus accumben Anatomy 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
208000006083 Hypokinesia Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
206010042008 Stereotypy Diseases 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
238000001792 White test Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
230000009194 climbing Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000008921 facial expression Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
208000013403 hyperactivity Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000203 mixture Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229960004851 pergolide Drugs 0.000 description 2
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000001242 postsynaptic effect Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
210000002637 putamen Anatomy 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
102000007527 Autoreceptors Human genes 0.000 description 1
108010071131 Autoreceptors Proteins 0.000 description 1
206010006100 Bradykinesia Diseases 0.000 description 1
229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010033864 Paranoia Diseases 0.000 description 1
208000027099 Paranoid disease Diseases 0.000 description 1
UHSKFQJFRQCDBE-UHFFFAOYSA-N Ropinirole hydrochloride Natural products CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
241000282695 Saimiri Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
229960000911 benserazide Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
210000005064 dopaminergic neuron Anatomy 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
229960003133 ergot alkaloid Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000035929 gnawing Effects 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009191 jumping Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940066974 medicated patch Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
230000009427 motor defect Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

DK275488A 1987-05-21 1988-05-19 Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom DK169609B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8712073		1987-05-21
GB878712073A GB8712073D0 (en)	1987-05-21	1987-05-21	Medicament

Publications (3)

Publication Number	Publication Date
DK275488D0 DK275488D0 (da)	1988-05-19
DK275488A DK275488A (da)	1988-11-22
DK169609B1 true DK169609B1 (da)	1994-12-27

Family

ID=10617727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK275488A DK169609B1 (da)	1987-05-21	1988-05-19	Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom

Country Status (20)

Country	Link
US (2)	US4824860A (fr)
EP (1)	EP0299602B1 (fr)
JP (1)	JPH062672B2 (fr)
AT (1)	ATE83659T1 (fr)
AU (1)	AU599792B2 (fr)
CA (1)	CA1305421C (fr)
DE (1)	DE3876877T2 (fr)
DK (1)	DK169609B1 (fr)
ES (1)	ES2052717T3 (fr)
GB (1)	GB8712073D0 (fr)
GR (1)	GR3007251T3 (fr)
HU (1)	HU201871B (fr)
IE (1)	IE63511B1 (fr)
LU (1)	LU90098I2 (fr)
MX (1)	MX9203543A (fr)
NL (1)	NL970006I2 (fr)
NZ (1)	NZ224709A (fr)
PH (1)	PH23867A (fr)
PT (1)	PT87542B (fr)
ZA (1)	ZA883602B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9008605D0 (en) *	1990-04-17	1990-06-13	Smith Kline French Lab	Process
GB9015095D0 (en) *	1990-07-09	1990-08-29	Smith Kline French Lab	Therapeutic method
WO1993023035A2 (fr) *	1992-05-18	1993-11-25	Smithkline Beecham Plc	Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson
GB9300309D0 (en) *	1993-01-08	1993-03-03	Smithkline Beecham Plc	Process
GB9511366D0 (en) *	1995-06-06	1995-08-02	Smithkline Beecham Plc	Novel formulations
GB9517062D0 (en) *	1995-08-18	1995-10-25	Scherer Ltd R P	Pharmaceutical compositions
US5807570A (en) *	1995-09-29	1998-09-15	Cygnus, Inc.	Transdermal administration of ropinirole and analogs thereof
GB9612752D0 (en) *	1996-06-19	1996-08-21	Smithkline Beecham Plc	Novel treatment
AU4088897A (en) *	1996-08-27	1998-03-19	American Home Products Corporation	4-aminoethoxy indolone derivatives
WO1999052870A1 (fr) *	1998-04-13	1999-10-21	American Home Products Corporation	4-amino-(ethylamino)-oxindoles utilises comme agonistes des autorecepteurs de la dopamine
US6176242B1 (en)	1999-04-30	2001-01-23	Medtronic Inc	Method of treating manic depression by brain infusion
US6218421B1 (en) *	1999-07-01	2001-04-17	Smithkline Beecham P.L.C.	Method of promoting smoking cessation
AR030557A1 (es)	2000-04-14	2003-08-27	Jagotec Ag	Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) *	2000-07-17	2001-08-21	Andrew J. Holman	Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
US7858602B2 (en) *	2000-10-16	2010-12-28	Rodriguez Victorio C	Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US6871098B2 (en) *	2000-10-30	2005-03-22	Medtronic, Inc.	Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
WO2004024163A1 (fr) *	2002-09-13	2004-03-25	Motac Neuroscience Limited	Traitement de troubles du mouvement associes aux noyaux gris centraux
ATE360415T1 (de) *	2002-09-17	2007-05-15	Motac Neuroscience Ltd	Behandlung von dyskinesie
DE10334188B4 (de) *	2003-07-26	2007-07-05	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) *	2003-07-26	2005-03-03	Schwarz Pharma Ag	Substituierte 2-Aminotetraline zur Behandlung von Depressionen
WO2005051488A1 (fr) *	2003-11-26	2005-06-09	Pfizer Products Inc.	Association d'agonistes de la dopamine et d'inhibiteurs de recaptage de la monoamine
DE10361258A1 (de) *	2003-12-24	2005-07-28	Schwarz Pharma Ag	Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US7378439B2 (en) *	2004-01-20	2008-05-27	Usv, Ltd.	Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
US20050197385A1 (en) *	2004-02-20	2005-09-08	Schwarz Pharma Ag	Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) *	2004-03-24	2006-07-06	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2007048034A2 (fr) *	2005-10-21	2007-04-26	Caritas St. Elizabeth Medical Center Of Boston, Inc.	Utilisation d'androgenes dans le traitement de la maladie de parkinson
ES2402376T3 (es) *	2006-04-06	2013-05-03	Nupathe Inc.	Implantes para el tratamiento de estados asociados con dopamina
WO2008001204A2 (fr) *	2006-06-29	2008-01-03	Antares Pharma Ipl Ag	Compositions transdermiques de pramipexole présentant des propriétés de perméation améliorées
TW200815045A (en) *	2006-06-29	2008-04-01	Jazz Pharmaceuticals Inc	Pharmaceutical compositions of ropinirole and methods of use thereof
US20090247537A1 (en) *	2008-03-25	2009-10-01	William Dale Overfield	Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) *	2008-05-05	2012-12-19	北京德众万全医药科技有限公司	一种罗匹尼罗的口服固体药物组合物
US20110195117A1 (en) *	2008-09-01	2011-08-11	Lupin Limited	Controlled release compositions of ropinirole
EP2452677A1 (fr)	2008-09-29	2012-05-16	Wockhardt Limited	Forme posologique à libération prolongée de ropinirole
WO2010044108A2 (fr)	2008-10-17	2010-04-22	Rubicon Research Private Limited	Formulations à libération contrôlée de ropinirole
US20100233259A1 (en) *	2008-12-12	2010-09-16	Pascal Grenier	Dosage form of ropinirole
MX2012012069A (es)	2010-04-30	2012-11-22	Teikoku Pharma Usa Inc	Composiciones transdermicas de propinilaminoindan.
KR101853082B1 (ko)	2011-03-24	2018-04-27	테이코쿠 팔마 유에스에이, 인코포레이티드	활성제층 및 활성제 변환층을 포함하는 경피 조성물
JP5913614B2 (ja)	2011-11-09	2016-04-27	テイコクファーマユーエスエーインコーポレーテッド	皮膚新生物の処置方法
JP6050896B2 (ja)	2012-11-02	2016-12-21	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダン経皮組成物
US20150313891A1 (en) *	2014-05-02	2015-11-05	Abbvie Inc.	Neuronal nicotinic agonists and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4588740A (en) *	1982-12-07	1986-05-13	Smithkline Beckman Corporation	Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones
US4452808A (en) *	1982-12-07	1984-06-05	Smithkline Beckman Corporation	4-Aminoalkyl-2(3H)-indolones

1987
- 1987-05-21 GB GB878712073A patent/GB8712073D0/en active Pending
1988
- 1988-05-16 PH PH36934A patent/PH23867A/en unknown
- 1988-05-16 IE IE146988A patent/IE63511B1/en not_active IP Right Cessation
- 1988-05-17 CA CA000566974A patent/CA1305421C/fr not_active Expired - Lifetime
- 1988-05-19 AU AU16445/88A patent/AU599792B2/en not_active Expired
- 1988-05-19 ES ES88304555T patent/ES2052717T3/es not_active Expired - Lifetime
- 1988-05-19 US US07/196,653 patent/US4824860A/en not_active Expired - Lifetime
- 1988-05-19 NZ NZ224709A patent/NZ224709A/en unknown
- 1988-05-19 EP EP88304555A patent/EP0299602B1/fr not_active Expired - Lifetime
- 1988-05-19 DK DK275488A patent/DK169609B1/da not_active IP Right Cessation
- 1988-05-19 DE DE8888304555T patent/DE3876877T2/de not_active Expired - Lifetime
- 1988-05-19 AT AT88304555T patent/ATE83659T1/de active
- 1988-05-20 JP JP63124816A patent/JPH062672B2/ja not_active Expired - Lifetime
- 1988-05-20 ZA ZA883602A patent/ZA883602B/xx unknown
- 1988-05-20 HU HU882611A patent/HU201871B/hu unknown
- 1988-05-20 PT PT87542A patent/PT87542B/pt not_active IP Right Cessation
1989
- 1989-03-13 US US07/322,386 patent/US4912126A/en not_active Expired - Lifetime
1992
- 1992-06-26 MX MX9203543A patent/MX9203543A/es unknown
1993
- 1993-03-05 GR GR930400472T patent/GR3007251T3/el unknown
1997
- 1997-02-05 NL NL970006C patent/NL970006I2/xx unknown
- 1997-07-16 LU LU90098C patent/LU90098I2/fr unknown

Also Published As

Publication number	Publication date
HU201871B (en)	1991-01-28
NL970006I2 (nl)	1997-10-01
NZ224709A (en)	1997-02-24
DE3876877T2 (de)	1993-04-29
PT87542B (pt)	1992-09-30
IE63511B1 (en)	1995-05-03
GR3007251T3 (fr)	1993-07-30
HK1000913A1 (en)	1998-05-08
DK275488A (da)	1988-11-22
EP0299602B1 (fr)	1992-12-23
ZA883602B (en)	1989-04-26
JPS63303966A (ja)	1988-12-12
PH23867A (en)	1989-11-23
ATE83659T1 (de)	1993-01-15
NL970006I1 (nl)	1997-04-01
EP0299602A2 (fr)	1989-01-18
HUT47217A (en)	1989-02-28
DK275488D0 (da)	1988-05-19
JPH062672B2 (ja)	1994-01-12
ES2052717T3 (es)	1994-07-16
LU90098I2 (fr)	1997-09-25
US4824860A (en)	1989-04-25
PT87542A (pt)	1989-05-31
IE881469L (en)	1988-11-21
DE3876877D1 (de)	1993-02-04
EP0299602A3 (en)	1990-06-06
CA1305421C (fr)	1992-07-21
AU599792B2 (en)	1990-07-26
MX9203543A (es)	1992-07-01
US4912126A (en)	1990-03-27
GB8712073D0 (en)	1987-06-24
AU1644588A (en)	1988-11-24

Legal Events

Date	Code	Title	Description
1994-12-27	B1	Patent granted (law 1993)
1997-03-24	CTFF	Application for supplementary protection certificate (spc) filed	Free format text: CA 1997 00011, 970131
1997-07-28	CTFG	Supplementary protection certificate (spc) issued	Free format text: CA 1997 00011, 970131, EXPIRES: 20110702
2008-06-09	PUP	Patent expired

Publication	Publication Date	Title
DK169609B1 (da)	1994-12-27	Anvendelse af 4-substituerede indoloner til fremstilling af medikamenter til behandling af Parkinsons sygdom
Devos et al.	2010	Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease
JP5582535B2 (ja)	2014-09-03	点眼投与による神経疾患または精神神経疾患の治療または予防
Berk et al.	2009	Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting
RS55585B1 (sr)	2017-06-30	Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
AU2002340971B2 (en)	2007-04-26	Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
JP2017533276A (ja)	2017-11-09	認知低下を処置するための方法
MXPA01009963A (es)	2003-07-14	Metodo para el tratamiento de padecimientos neurologicos o neuropsiquiatricos.
CN107635555A (zh)	2018-01-26	丁螺环酮代谢物的用途
Korsgaard et al.	1982	The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia: A New β-Aminobutyric Acid Agonist
EA015514B1 (ru)	2011-08-30	Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
KR20030053475A (ko)	2003-06-28	5-ｈｔ3 및 신경세포의 니코틴작용성 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물을 이용한 치료방법 및 이 화합물을 함유하는 약학적 조성물
JP2019001798A (ja)	2019-01-10	活動意欲向上剤
WO2024052880A1 (fr)	2024-03-14	Utilisation de mdma pour le traitement de troubles liés au stress
RU2706001C2 (ru)	2019-11-13	Способ для лечения болезней мотонейронов
WO2002067927A1 (fr)	2002-09-06	Composes de carbamate destines a la prevention ou au traitement de troubles psychotiques
Sandyk	1994	A drug naive parkinsonian patient successfully treated with weak electromagnetic fields
CN101584692A (zh)	2009-11-25	左旋千金藤啶碱(l-SPD)衍生物的用途
Klawans Jr et al.	1972	Observations on the use of methysergide in Huntington's chorea
Weiner et al.	1979	Dopaminergic antagonism of L‐5‐hydroxytryptophan‐induced myoclonic jumping behavior
HK1000913B (en)	1998-05-08	Use of indolone derivatives for the preparation of medicaments for the treatment of parkinsons disease
CA2654719A1 (fr)	2007-12-21	Preparations combinees contenant le slv308 et de la l-dopa
CN120919140A (zh)	2025-11-11	一种艾司氯胺酮与米氮平协同的抗抑郁药物组合物及应用
CN106265612A (zh)	2017-01-04	龙血素c在制备防治中枢神经系统疾病药物中的应用
Dickinson et al.	1991	Effects of idazoxan on 5-hydroxytryptamine-mediated behaviour in the mouse and rat